Targeted therapies, such as treatment with the BRAF inhibitor vemurafenib in BRAF-mutated MM patients or BCL-2 inhibition with venetoclax for MM with t [4, 14] are currently being used for treatment of relapsed and refractory MM (RRMM) [15]. The gene discussed is BCL2; the disease is Miyoshi myopathy.